ML-15 The future direction of treatment development for primary central nervous system lymphoma (PCNSL)

Purpose: We found that the combination of high-dose Methotrexate (HD-MTX)-based therapy and histone deacetylase inhibitor (HDACI) had a therapeutic effect on PCNSL. In addition, this year, tirabrutinib, a Bruton’s tyrosine kinase inhibitor, was approved for marketing as a single agent for relapsed/r...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neurooncol Adv
Main Authors: Shinojima, Naoki, Fujimoto, Kenji, Yamamoto, Takahiro, Ohta, Kazutaka, Takezaki, Tatsuya, Kuroda, Jun-ichiro, Makino, Keishi, Mukasa, Akitake
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Supplement Abstracts
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7699052/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa143.075
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki